|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
BETABLOCKERS NOT ONLY BLOCK THE PULMONARY EFFECTS OF BETA-AGONISTS LIKE ALBUTEROL BUT MAY PRODUCE SEVERE BRONCHOSPASM IN ASTHMATICS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
CHLORPROMAZINE WHEN USED CONCOMITANTLY RESULTS IN INCREASED PLASMA LEVELS OF BOTH THE DRUGS
|
CHLORPROMAZINE WHEN USED CONCOMITANTLY RESULTS IN INCREASED PLASMA LEVELS OF BOTH THE DRUGS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
FRUSEMIDE MAY ADD TO OR POTENTIATE THE THERAPEUTIC OF OTHER ANTIHYPERTENSIVE DRUGS
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CHLORPROMAZINE WHEN USED CONCOMITANTLY RESULTS IN INCREASED PLASMA LEVELS OF BOTH THE DRUGS
|
BETABLOCKERS CAN BOTH INCREASE HYPOGLYCEMIA & MASK THE TYPICAL SYMPATHETIC HYPOGLYCEMIC WARNING SIGNS
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
THEOPHYLLIN PLASMA CONCENTRATION IS RAISED BY THE DRUG
|
CIMETIDINE INCREASES ITS PLASMA CONCENTRATION AND HENCE BIOAVAILABILITY
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CLONIDINE CO-ADMINISTRATION WITH AGENTS KNOWN TO AFFECT SINUS NODE FUNCTION OR A.V. NODAL CONDUCTION LIKE DIGOXIN,CALCIUM CHANNEL BLOCKER & BETABLOCKER MAY CAUSE BRADYCARDIA & A.V. BLOCK
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
INCREASED HYPOTENSIVE EFFECT IS SEEN
|
POSSIBLE POTENTIATION OF BRADYCARDIA, SINUS ARREST AND AV BLOCK
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CALCIUM CHANNEL BLOCKERS & BETABLOCKERS ARE USUALLY WELL TOLERATED BUT THERE ARE OCCASIONAL REPORTS OF INCREASED CHANCES OF CHF, SEVERE HYPOTENSION, BRADYCARDIA, A.V. BLOCK & EXACERBATION OF ANGINA
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
CALCIUM CHANNEL BLOCKERS & BETABLOCKERS ARE USUALLY WELL TOLERATED BUT THERE ARE OCCASIONAL REPORTS OF INCREASED CHANCES OF CHF, SEVERE HYPOTENSION, BRADYCARDIA, A.V. BLOCK & EXACERBATION OF ANGINA
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
CHLORPROMAZINE WHEN USED CONCOMITANTLY RESULTS IN INCREASED PLASMA LEVELS OF BOTH THE DRUGS
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
CONCOMITANT USE MAY INCREASE RISK OF VASCULAR OCCLUSION
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
BETABLOCKERS CAUSE PARADOXICAL ANTAGONISM OF HYPOTENSIVE EFFECT OF METHYLDOPA
|
CHLORPROMAZINE WHEN USED CONCOMITANTLY RESULTS IN INCREASED PLASMA LEVELS OF BOTH THE DRUGS
|
PROPOXYPHENE & DEXTROPROPOXYPHENE INHIBIT LIVER METABOLISM OF BENZODIAZEPINES, BETABLOCKERS, CARBAMAZEPINE, PHENYTOIN & WARFARIN, SO REDUCE THEIR DOSE BY 1/3
|
THE HYPOTENSIVE EFFECTS OF BETA BLOCKERS MAY BE DIMINISHED BY THE CONCOMITANT ADMINISTRATION OF ASPIRIN DUE TO INHIBITION OF RENAL PROSTAGLANDINS, LEADING TO DECREASED RENAL BLOOD FLOW AND SALT AND FLUID RETENTION
|
CONCURRENT ADMINISTRATION MAY CAUSE BRADYCARDIA, MYOCARDIAL DEPRESSION OR A.V. BLOCK
|
BETABLOCKERS ESPECIALLY PROPRANOLOL MAY REDUCE RENAL CLEARANCE OF THE DRUG LEADING TO INCREASED BIOAVAILABILITY
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
NSAIDS CONCURRENT ADMINISTRATION MAY DECREASE THE ANTIHYPERTENSIVE EFFECT OF THE DRUG
|
CONCOMITANT USE OF DIGOXIN AND BETA-ANDRENERGIC BLOCKERS MAY RESULT IN THE ADDITIVE EFFECTS ON AV NODE CONDUCTION
|
ANTACIDS CAN DELAY & DECREASE ABSORPTION
|
CONCOMITANT USE OF DILTIAZEM WITH BETA BLOCKERS MAY RESULT IN ADDITIVE EFFECT ON CARDIAC CONDUCTION ; I.V. DILTIAZEM AND I.V. BETA-BLOCKERS SHOULD NOT BE ADMINISTRATION TOGETHER OR IN CLOSE PROXIMITY
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS MAY PRODUCE BRADYCARDIA & HYPOTENSION
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
ADRENALINE RESPONSE MAY BE REDUCED IN PATIENTS ON LONG TERM BETABLOCKERS
|